KVAC

Keen Vision Acquisition Corp

12.55

Jul 22 • 3:55 PM ET +0.29 (2.37%)

12.27

Aftermarket • 4:15 PM ET -0.28 (-2.23%)

Financial Shell Companies USA Micro NASD

Index	-
Market Cap	69.41M
Enterprise Value	72.19M
Income	1.43M
Sales	0.00M
Book/sh	1.05
Cash/sh	0.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	2
IPO	Sep 15, 2023

P/E	85.37
Forward P/E	-
PEG	-
P/S	-
P/B	11.94
P/C	6941.40
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.02
Current Ratio	0.02
Debt/Eq	0.48
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	0.15
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-50.57%
Sales Y/Y TTM	-
EPS Q/Q	-76.76%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	80.20%
Insider Trans	0.00%
Inst Own	21.22%
Inst Trans	-
ROA	3.37%
ROE	3.95%
ROIC	24.77%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	2.09%
SMA50	3.79%
SMA200	8.96%
Trades

Shs Outstand	5.51M
Shs Float	1.09M
Short Float	0.02%
Short Ratio	0.04
Short Interest	0.00M
52W High	12.55 0.00%
52W Low	11.37 10.38%
Volatility	0.36% 0.39%
ATR (14)	0.12
RSI (14)	65.43
Beta	-0.03
Rel Volume	0.42
Avg Volume	4.99K
Volume	2,095

Perf Week	1.87%
Perf Month	2.87%
Perf Quarter	3.89%
Perf Half Y	4.58%
Perf YTD	6.81%
Perf Year	9.13%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	12.26
Price	12.55
Change	2.37%

Jul-15-25 08:00AM	Medera and University of Kansas Medical Center Announce First Patient Treated in Pioneering Gene Therapy Trial for Duchenne Muscular Dystrophy Associated Cardiomyopathy (GlobeNewswire)
Jun-24-25 08:00AM	Mederas Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome (GlobeNewswire)
Jun-13-25 08:00AM	Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025 (GlobeNewswire)
May-19-25 08:00AM	Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress (GlobeNewswire)
May-12-25 08:00AM	Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress (GlobeNewswire)
08:00AM	Loading…
Apr-01-25 08:00AM	Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit (GlobeNewswire)
Mar-20-25 08:00AM	Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction (GlobeNewswire)
Mar-11-25 12:53PM	Medera Completes Patient Dosing for Heart Failure Treatment (Exec Edge)
09:09AM	Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction (GlobeNewswire)
Feb-10-25 08:00AM	Mederas Novoheart Expands Human Cardiac Research with CTScreen Installation at University Medical Center, Utrecht (GlobeNewswire)
Feb-07-25 08:00AM	Medera, Inc. to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Dec-18-24 08:00AM	Medera's Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening (GlobeNewswire)
Dec-10-24 08:00AM	Medera's Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing (GlobeNewswire)
Oct-31-24 08:00AM	Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology (PR Newswire)
Oct-24-24 08:00AM	Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction (PR Newswire)
11:57AM	Loading…
Sep-05-24 11:57AM	Medera to List on NASDAQ After Merger with Keen Vision Acquisition Corp. (Exec Edge)
08:00AM	Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation (PR Newswire)

Keen Vision Acquisition Corp. is a blank check company, which engages in effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, and reorganization or similar business combination. The company was founded on June 18, 2021 and is headquartered in Summit, NJ.

FounderMr. Ka Chun Wong

FounderMr. Kon Man Wong

CFO & DirectorMr. Alex Davidkhanian

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KVAC

Keen Vision Acquisition Corp

Upgrade your Finviz experience